

29.05.18

## ASX ANNOUNCEMENT

ASX Market Announcements Australian Securities Exchange Limited 10<sup>th</sup> Floor, 20 Bond Street SYDNEY NSW 2000

## **CONFIRMATION OF GRANT OF ASX WAIVER**

Admedus Limited (ASX:AHZ) (the **Company**) announced on 21 May 2018 that Mr Mathew Ratty had resigned as a director of the Company on 20 May 2018 and would not seek relection as a director of the Company at its Annual General Meeting (for the period July – December 2017) on 24 May 2018 (the **2018 AGM**). Mr Mathew Ratty had been recorded in the Company's Notice of the 2018 AGM as seeking re-election.

ASX granted the Company a waiver of Listing Rule 14.5 not to hold an election of directors in the 2018 calendar year, on condition that:

- (a) all remaining non-executive directors had been elected or re-elected at the Company's prior Annual General Meeting held on 16 November 2017; and
- (b) no other candidate was nominated as a candidate for election at the 2018 AGM as a director within the relevant minimum time period before the 2018 AGM in accordance with Listing Rule 14.3 or the Company's constitution.

While section 250R(1)(b) of the *Corporations Act 2001* (Cth) permits the election of directors at an annual general meeting without notice as an item of ordinary business, the Company's constitution states that only matters that appear in the notice of meeting can be dealt with at the relevant meeting. Accordingly, the Board of Directors were not in a position to nominate another candidate on the basis of the short period between the resignation of Mr Mathew Ratty and the 2018 AGM, and the inability to provide proper notice to shareholders of another candidate.

For these reasons, there was no election of directors during calendar year 2018.

## **ENDS**



## **About Admedus Limited**

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Website: <u>www.admedus.com</u>

Facebook: www.facebook.com/Admedus

Twitter: @Admedus

For more information, please contact:

Admedus Limited

Barbara Ferres

+61 7 3152 3216

communications@admedus.com